Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
PURPOSE PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. Here we investigate the role of CDK4/6… Continue Reading
Purpose To characterize diarrhea events in patients with cancer treated with lapatinib as monotherapy or in combination with capecitabine or taxanes. Patients and methods Eleven clinical trials… Continue Reading
LBA502 Background: The growth of hormone receptor (HR) positive breast cancer (BC) is dependent on the cyclin dependent kinases CDK4/6, that promote G1-S phase cell cycle progression. Resistance to… Continue Reading
The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) charged the Biomarker Task Force to develop recommendations to improve the decisions about incorporation of… Continue Reading
CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers. Early changes… Continue Reading
The popularization of television has led to a reduction of physical activity during infancy. In addition, food advertisements on TV can attract the attention and desires of children. The objectives… Continue Reading
PURPOSE It has been suggested that a subgroup of human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with chromosome 17 (Chr-17) polysomy benefit from HER2-directed… Continue Reading
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA In spite of the dramatically improved outlook for patients with ER+ breast cancer, a subset of patients are intrinsically… Continue Reading
512Background: PALOMA-3 is a randomized, double-blind, phase III study comparing P+F with fulvestrant plus placebo (F+Pla) in pre- and postmenopausal women with HR+/HER2– MBC that progressed on pri...
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #3133 Background: HER2 overexpression has been shown to upregulate VEGF expression in pre-clinical breast cancer models.… Continue Reading